Skip to content
Trial Eligibility
Menu

Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT07238790

This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • IBS (Irritable Bowel Syndrome)
  • Diarrhea

Eligibility basics and study details

Study type
Interventional
Phase
Early Phase 1
Ages
18 to 65 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Stanford University
Last updated on ClinicalTrials.gov
November 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 2

  • Stanford Digestive Health Clinic · Redwood City, CA
  • Stanford University · Stanford, CA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.